ArticleOphthalmology and therapy2025

Cenegermin for the Treatment of Moderate or Severe Neurotrophic Keratopathy: Results from a Prospective, Phase IV, Open-Label Study in China.

Suxia Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.